5 innovadores medicamentos chinos, incluyendo inhibidores de:
🧬 KRAS G12C
🧬 EGFR de tercera generación
🧬 EGFR exon 20

#Fulzerasib #Sunvozertinib #Limertinib #Glecirasib #Garsorasib #Cáncer #Oncología #TerapiaDirigida #InnovaciónMédica #KRAS
#KRASG12C #EGFR #EGFRexon20 #DengYueMedicinasEnHongKong

Jacobio Pharma Reports Strong Growth and Breakthroughs in Interim Results for 2025 Jacobio Pharma has announced robust interim results for 2025, highlighting significant revenue growth, reduced losses, and promising advancements in its pipeline of cancer therapies.

Jacobio Pharma Reports Strong Growth and Breakthroughs in Interim Results for 2025 #China #Beijing #cancer_therapy #Jacobio_Pharma #glecirasib

Jacobio Pharma Reports Impressive Annual Revenue Growth For 2024 Jacobio Pharma has announced its annual results for 2024, showcasing strong revenue growth and significant advancements in cancer treatment developments.

Jacobio Pharma Reports Impressive Annual Revenue Growth For 2024 #China #Beijing #Jacobio_Pharma #R&D #glecirasib